Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders-Reference-Cited by-同舟云学术

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

Published:2012-01-30 Issue:3 Volume:55 Page:742-748
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Chayama Kazuaki,Takahashi Shoichi,Toyota Joji,Karino Yoshiyasu,Ikeda Kenji,Ishikawa Hiroki,Watanabe Hideaki,McPhee Fiona,Hughes Eric,Kumada Hiromitsu

Publisher

Wiley

Subject

Hepatology

Reference32 articles.

1. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002;Armstrong;Ann Intern Med,2006

2. World Health Organization http://www.who.int/csr/disease/hep atitis/whocdscsrlyo2003/en/index4.html 2011

3. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy;Legrand-Abravanel;J Med Virol,2009

4. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy;Nicot;J Med Virol,2011

5. A systematic review of hepatitis C virus epidemiology in Europe, Canada, and Israel;Cornberg;Liver Int,2011

Cited by 319 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed cell death-1 is involved with peripheral blood immune cell profiles in patients with hepatitis C virus antiviral therapy;PLOS ONE;2024-05-23

2. mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response;Journal of Gastroenterology and Hepatology;2024-02-25

3. Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study;Medicina;2023-08-08

4. Validation of a Cost-Effective RP-HPLC Method for Quantitative Investigation of Daclatasvir Dihydrochloride in Pharmaceutical Formulations;Journal of Chemistry;2023-08-03

5. Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection;JGH Open;2022-05